Ignacio I. Wistuba focuses on Lung cancer, Cancer research, Adenocarcinoma, Cancer and Pathology. His Lung cancer research incorporates elements of Carcinoma, Lung and Epidermal growth factor receptor. His study in Cancer research is interdisciplinary in nature, drawing from both Mutation, KRAS, Molecular biology and microRNA.
His Adenocarcinoma study integrates concerns from other disciplines, such as Carcinogenesis, Epithelial–mesenchymal transition, Small Cell Lung Carcinoma and Loss of heterozygosity. Ignacio I. Wistuba has included themes like Biomarker, Blockade and Bioinformatics in his Cancer study. His work investigates the relationship between Pathology and topics such as Cell that intersect with problems in Vimentin, Adenocarcinoma of the lung and Cell growth.
His main research concerns Lung cancer, Cancer research, Cancer, Internal medicine and Pathology. His Lung cancer study combines topics from a wide range of disciplines, such as KRAS, Carcinoma, Lung and Adenocarcinoma. The Cancer research study combines topics in areas such as Cell, Carcinogenesis, Cancer cell, Immune system and Metastasis.
His Cancer research includes themes of PI3K/AKT/mTOR pathway, Immunology and Bioinformatics. The study incorporates disciplines such as Gastroenterology and Oncology in addition to Internal medicine. His work carried out in the field of Oncology brings together such families of science as Stage and Biomarker.
Ignacio I. Wistuba mainly focuses on Cancer research, Lung cancer, Internal medicine, Oncology and Immune system. His work deals with themes such as Immune checkpoint, Immunotherapy, T cell and Adenocarcinoma, which intersect with Cancer research. His Adenocarcinoma research is multidisciplinary, incorporating perspectives in Carcinogenesis, Lung and Pathology.
His research in Lung cancer is mostly concerned with Non small cell. His Oncology study which covers Nivolumab that intersects with Ipilimumab. Ignacio I. Wistuba interconnects Computational biology and Disease in the investigation of issues within Cancer.
His scientific interests lie mostly in Lung cancer, Cancer research, Internal medicine, Oncology and Immunotherapy. His study with Lung cancer involves better knowledge in Pathology. His biological study spans a wide range of topics, including Thyroid and Adenocarcinoma.
The study incorporates disciplines such as Cell, Cancer cell, T cell, Immune system and Metastasis in addition to Cancer research. His studies deal with areas such as Chemotherapy, Nivolumab, Atezolizumab, Immune checkpoint inhibitors and Major Pathologic Response as well as Oncology. His study in Immunotherapy is interdisciplinary in nature, drawing from both Immunohistochemistry and Targeted therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
Hisayuki Shigematsu;Hisayuki Shigematsu;Li Lin;Takao Takahashi;Masaharu Nomura.
Journal of the National Cancer Institute (2005)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding;Gad Getz;David A. Wheeler;Elaine R. Mardis.
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis;Elisabeth Brambilla;Andrew G. Nicholson;Yasushi Yatabe.
Journal of Thoracic Oncology (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner.
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
Hisayuki Shigematsu;Hisayuki Shigematsu;Takao Takahashi;Masaharu Nomura;Kuntal Majmudar.
Cancer Research (2005)
KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Erminia Massarelli;Marileila Varella-Garcia;Ximing Tang;Ana C. Xavier.
Clinical Cancer Research (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: